Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Atazanavir sulphate

Nature Reviews Drug Discovery volume 2, pages 857–858 (2003)Cite this article

Abstract

In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favourable dosing schedule and side-effect profile lead to success in this crowded and complex market?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Atazanavir sulphate.
Figure 2: Market for anti-HIV drugs.

References

  1. Pomerantz, R. J. & Horn, D. L. Twenty years of therapy for HIV-1 infection. Nature Med. 9, 867–873 (2003).

    Article  CAS  Google Scholar 

  2. Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Discov. 2, 624–634 (2003).

    Article  CAS  Google Scholar 

  3. Fässler, A. et al. Aza-peptide analogues as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. J. Med. Chem. 39, 3203–3216 (1996).

    Article  Google Scholar 

  4. Priestle, J. P. et al. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CPG 53820, a novel pseudosymmetric inhibitor. Structure 3, 381–389 (1995).

    Article  CAS  Google Scholar 

  5. Bold, G. et al. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41, 3387–3401 (1998).

    Article  CAS  Google Scholar 

  6. Robinson, B. S. et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44, 2093–2099 (2000).

    Article  CAS  Google Scholar 

  7. FDA Drug Approvals List [online] (cited 9 September 2003). <http://www.fda.gov/cder/foi/label/2003/21567_reyataz_lbl.pdf> (2003).

  8. Albrecht, M. A. et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N. Eng. J Med. 345, 398–407 (2001).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Drug Discovery,

    Aarti Raja, John Lebbos & Peter Kirkpatrick

  2. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Aarti Raja, John Lebbos & Peter Kirkpatrick

Authors
  1. Aarti Raja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Lebbos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aarti Raja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raja, A., Lebbos, J. & Kirkpatrick, P. Atazanavir sulphate. Nat Rev Drug Discov 2, 857–858 (2003). https://doi.org/10.1038/nrd1232

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1232

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing